276 related articles for article (PubMed ID: 34764005)
1. Hepatic steatosis and development of type 2 diabetes: Impact of chronic hepatitis B and viral specific factors.
Yu MW; Lin CL; Liu CJ; Huang YW; Hu JT; Wu WJ; Wu CF
J Formos Med Assoc; 2022 Aug; 121(8):1478-1487. PubMed ID: 34764005
[TBL] [Abstract][Full Text] [Related]
2. Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B.
Mak LY; Hui RW; Fung J; Liu F; Wong DK; Cheung KS; Yuen MF; Seto WK
J Hepatol; 2020 Oct; 73(4):800-806. PubMed ID: 32504663
[TBL] [Abstract][Full Text] [Related]
3. Impact of NAFLD on the outcome of patients with chronic hepatitis B in Asia.
Yang M; Wei L
Liver Int; 2022 Aug; 42(9):1981-1990. PubMed ID: 35373500
[TBL] [Abstract][Full Text] [Related]
4. Distinct effects of hepatic steatosis and metabolic dysfunction on the risk of hepatocellular carcinoma in chronic hepatitis B.
Huang SC; Su TH; Tseng TC; Chen CL; Hsu SJ; Liao SH; Hong CM; Liu CH; Lan TY; Yang HC; Liu CJ; Chen PJ; Kao JH
Hepatol Int; 2023 Oct; 17(5):1139-1149. PubMed ID: 37247045
[TBL] [Abstract][Full Text] [Related]
5. Reduced hepatic steatosis is associated with higher risk of hepatocellular carcinoma in chronic hepatitis B infection.
Mak LY; Hui RW; Fung J; Liu F; Wong DK; Li B; Cheung KS; Yuen MF; Seto WK
Hepatol Int; 2021 Aug; 15(4):901-911. PubMed ID: 34152534
[TBL] [Abstract][Full Text] [Related]
6. Clinical and virological characteristics post HBsAg seroclearance in hepatitis B virus carriers with hepatic steatosis versus those without.
Chu CM; Lin DY; Liaw YF
Dig Dis Sci; 2013 Jan; 58(1):275-81. PubMed ID: 22903182
[TBL] [Abstract][Full Text] [Related]
7. Risk of hepatic decompensation but not hepatocellular carcinoma decreases over time in patients with hepatitis B surface antigen loss.
Yip TC; Wong VW; Lai MS; Lai JC; Hui VW; Liang LY; Tse YK; Chan HL; Wong GL
J Hepatol; 2023 Mar; 78(3):524-533. PubMed ID: 36463985
[TBL] [Abstract][Full Text] [Related]
8. Chronic hepatitis B infection with concomitant hepatic steatosis: Current evidence and opinion.
Shi YW; Yang RX; Fan JG
World J Gastroenterol; 2021 Jul; 27(26):3971-3983. PubMed ID: 34326608
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of hepatosteatosis in patients with chronic hepatitis B virus infection.
Sefa Sayar M; Bulut D; Acar A
Arab J Gastroenterol; 2023 Feb; 24(1):11-15. PubMed ID: 35688683
[TBL] [Abstract][Full Text] [Related]
10. Steatosis, HBV-related HCC, cirrhosis, and HBsAg seroclearance: A systematic review and meta-analysis.
Mao X; Cheung KS; Peng C; Mak LY; Cheng HM; Fung J; Peleg N; Leung HH; Kumar R; Lee JH; Shlomai A; Yuen MF; Seto WK
Hepatology; 2023 May; 77(5):1735-1745. PubMed ID: 36111362
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease.
Pais R; Rusu E; Zilisteanu D; Circiumaru A; Micu L; Voiculescu M; Poynard T; Ratziu V
Eur J Intern Med; 2015 Jan; 26(1):30-6. PubMed ID: 25553983
[TBL] [Abstract][Full Text] [Related]
12. Impact of fatty liver on long-term outcomes in chronic hepatitis B: a systematic review and matched analysis of individual patient data meta-analysis.
Wong YJ; Nguyen VH; Yang HI; Li J; Le MH; Wu WJ; Han NX; Fong KY; Chen E; Wong C; Rui F; Xu X; Xue Q; Hu XY; Leow WQ; Goh GB; Cheung R; Wong G; Wong VW; Yu MW; Nguyen MH
Clin Mol Hepatol; 2023 Jul; 29(3):705-720. PubMed ID: 37157776
[TBL] [Abstract][Full Text] [Related]
13. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues.
Yip TC; Wong GL; Chan HL; Tse YK; Lam KL; Lui GC; Wong VW
J Hepatol; 2019 Mar; 70(3):361-370. PubMed ID: 30367899
[TBL] [Abstract][Full Text] [Related]
14. No influence of hepatic steatosis on the 3-year outcomes of patients with quiescent chronic hepatitis B.
Chang JW; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Kim SU
J Viral Hepat; 2021 Nov; 28(11):1545-1553. PubMed ID: 34382730
[TBL] [Abstract][Full Text] [Related]
15. Association Between Fatty Liver and Cirrhosis, Hepatocellular Carcinoma, and Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B.
Li J; Yang HI; Yeh ML; Le MH; Le AK; Yeo YH; Dai CY; Barnett S; Zhang JQ; Huang JF; Trinh HN; Wong C; Wong C; Hoang JK; Cheung R; Yu ML; Nguyen MH
J Infect Dis; 2021 Jul; 224(2):294-302. PubMed ID: 33249474
[TBL] [Abstract][Full Text] [Related]
16. Impact of PNPLA3 p.I148M and Hepatic Steatosis on Long-Term Outcomes for Hepatocellular Carcinoma and HBsAg Seroclearance in Chronic Hepatitis B.
Hsueh RC; Wu WJ; Lin CL; Liu CJ; Huang YW; Hu JT; Wu CF; Sung FY; Liu WJ; Yu MW
J Hepatocell Carcinoma; 2022; 9():301-313. PubMed ID: 35433529
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis B virus infection and risk of non-alcoholic fatty liver disease: A population-based cohort study.
Zhu L; Jiang J; Zhai X; Baecker A; Peng H; Qian J; Zhou M; Song C; Zhou Y; Xu J; Liu H; Hang D; Hu Z; Shen H; Zhang ZF; Zhu F
Liver Int; 2019 Jan; 39(1):70-80. PubMed ID: 30025200
[TBL] [Abstract][Full Text] [Related]
18. Systematic review with meta-analysis: development of hepatocellular carcinoma in chronic hepatitis B patients with hepatitis B surface antigen seroclearance.
Liu F; Wang XW; Chen L; Hu P; Ren H; Hu HD
Aliment Pharmacol Ther; 2016 Jun; 43(12):1253-61. PubMed ID: 27117732
[TBL] [Abstract][Full Text] [Related]
19. Chronic hepatitis B associated with hepatic steatosis, insulin resistance, necroinflammation and fibrosis.
Yilmaz B; Koklu S; Buyukbayram H; Yalçin K; Korkmaz U; Posul E; Can G; Kurt M
Afr Health Sci; 2015 Sep; 15(3):714-8. PubMed ID: 26957957
[TBL] [Abstract][Full Text] [Related]
20. [Analysis of clinical and pathological features of chronic hepatitis B combined with metabolic-associated fatty liver disease].
Shang MY; Chen YZ; Bao J; Tong YL
Zhonghua Gan Zang Bing Za Zhi; 2023 Feb; 31(2):126-132. PubMed ID: 37137826
[No Abstract] [Full Text] [Related]
[Next] [New Search]
